Exploration of Targeted Anti-tumor Therapy

Table 1. Multivariate analysis of EGFR and ALK positive vs. double negative groups

Predictor variables	Level	EGFR positive vs. negative		ALK positive vs. negative
Predictor variables	Level	Sig.	OR	Sig.	OR
Intercept	-	0.691	-	0.618	-
Number of lesions	-	0.061	1.028 (0.999, 1.057)	0.013	1.037 (1.008, 1.068)
Smoking history	Yes	0.147	0.316 (0.066, 1.499)	0.037	0.208 (0.047, 0.913)
Smoking history	No	REF
Histology	Squamous	0.826	0.769 (0.074, 7.949)	0.164	0.160 (0.012, 2.112)
Histology	Adenocarcinoma	REF
T2W	Hypointense	0.413	0.424 (0.054, 3.311)	0.123	4.099 (0.684, 24.573)
	Heterogeneous	0.707	0.630 (0.057, 6.977)	0.467	0.360 (0.023, 5.661)
	Hyperintense	REF
T2 borders	Defined	REF
T2 borders	Fuzzy	0.009	7.858 (1.681, 36.742)	0.242	2.401 (0.554, 10.408)
Hemorrhage	Present	0.025	6.490 (1.267, 33.240)	0.771	0.787 (0.157, 3.952)
Hemorrhage	Absent	REF
Diffusion restriction	Central	0.302	0.329 (0.040, 2.721)	0.479	0.402 (0.032, 4.994)
	Complete	0.058	0.100 (0.009, 1.080)	0.106	0.113 (0.008, 1.586)
	Peripheral	0.023	0.044 (0.003, 0.650)	0.074	4.227 (0.867, 20.600)
	None	REF
Enhancement pattern	Patchy	0.198	3.606 (0.51, 25.478)	0.292	2.946 (0.394, 22.004)
	Ring	0.715	1.43 (0.209, 9.775)	0.005	14.879 (2.278, 97.189)
	Homogeneous	REF
Meningeal involvement	Present	0.594	1.584 (0.292, 8.591)	0.045	6.394 (1.046, 39.071)
Meningeal involvement	Absent	REF
Lung metastasis	Present	0.054	6.329 (0.967, 41.427)	0.007	12.47 (1.995, 77.925)
	Absent	REF

Return to article view

Sig.: significance; OR: odds ratio; -: not applicable; REF: reference; T2W: T2 weighted. Data in parentheses () are 95% CIs

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002158_sup_1.pdf.

Declarations

Author contributions

AM: Conceptualization, Project administration, Investigation, Methodology, Supervision, Validation, Writing—review & editing. GB: Conceptualization, Data curation, Formal analysis, Investigation, Writing—review & editing, Writing—original draft. ST: Supervision. UB: Data curation, Formal analysis, Software. SW, UA, AKJ, VP, VN, NM, AT, JPA, SY, RK, AP, NP, and KP: Data curation, Investigation. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was conducted after clearance from Institutional Ethics Committee (3296) and conducted in accordance with the guidelines of the Indian Council of Medical Research 2017. The research of this article meets the requirements of the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The datasets generated in this study are available on request to Abhishek Mahajan (drabhishek.mahajan@yahoo.in).

Funding

Not applicable.

Copyright

References

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27. [DOI] [PubMed]

Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. [DOI] [PubMed]

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. [DOI] [PubMed]

Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al.; German Respiratory Society; German Cancer Society. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2011;65:39–59. [DOI] [PubMed]

Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin. 2003;21:1–23. [DOI] [PubMed]

Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300. [DOI] [PubMed] [PMC]

Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res. 1997;3:2696–702. [PubMed]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–75. [DOI] [PubMed] [PMC]

10.

Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–80. [DOI] [PubMed]

11.

Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–6. [DOI] [PubMed] [PMC]

12.

Daniels MG, Bowman RV, Yang IA, Govindan R, Fong KM. An emerging place for lung cancer genomics in 2013. J Thorac Dis. 2013;5:S491–7. [DOI] [PubMed] [PMC]

13.

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. [DOI] [PubMed] [PMC]

14.

Mahajan A, Moiyadi AV, Jalali R, Sridhar E. Radiogenomics of glioblastoma: a window into its imaging and molecular variability. Cancer Imaging. 2015;15:P14. [DOI] [PMC]

15.

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6. [DOI] [PubMed] [PMC]

16.

Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31:1803–5. [DOI] [PubMed]

17.

Hazlett HC, Gu H, Munsell BC, Kim SH, Styner M, Wolff JJ, et al. Early brain development in infants at high risk for autism spectrum disorder. Nature. 2017;542:348–51. [DOI] [PubMed] [PMC]

18.

Lakhani P, Sundaram B. Deep learning at chest radiography: automated classification of pulmonary tuberculosis by using convolutional neural networks. Radiology. 2017;284:574–82. [DOI] [PubMed]

19.

Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115–8. Erratum in: Nature. 2017;546:686. [DOI] [PubMed] [PMC]

20.

Mehta R, Filos A, Baid U, Sako C, McKinley R, Rebsamen M, et al. QU-BraTS: MICCAI BraTS 2020 challenge on quantifying uncertainty in brain tumor segmentation-analysis of ranking metrics and benchmarking results. J Mach Learn Biomed Imaging. 2022;2022. [PubMed] [PMC]

21.

Kurian NC, Sethi A, Konduru AR, Mahajan A, Rane SU. A 2021 update on cancer image analytics with deep learning. WIREs Data Mining Knowl Discov. 2021;11:e1410. [DOI]

22.

Baid U, Rane SU, Talbar S, Gupta S, Thakur MH, Moiyadi A, et al. Overall survival prediction in glioblastoma with radiomic features using machine learning. Front Comput Neurosci. 2020;14:61. [DOI] [PubMed] [PMC]

23.

Baid U, Talbar S, Rane S, Gupta S, Thakur MH, Moiyadi A, et al. A novel approach for fully automatic intra-tumor segmentation with 3D U-Net architecture for gliomas. Front Comput Neurosci. 2020;14:10. [DOI] [PubMed] [PMC]

24.

Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA. 2017;318:2211–23. [DOI] [PubMed] [PMC]

25.

Wang K, Lu X, Zhou H, Gao Y, Zheng J, Tong M, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut. 2019;68:729–41. [DOI] [PubMed] [PMC]

26.

Parmar C, Leijenaar RT, Grossmann P, Rios Velazquez ER, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep. 2015;5:11044. [DOI] [PubMed] [PMC]

27.

Vaidya T, Agrawal A, Mahajan S, Thakur MH, Mahajan A. The continuing evolution of molecular functional imaging in clinical oncology: the road to precision medicine and radiogenomics (part I). Mol Diagn Ther. 2019;23:1–26. [DOI] [PubMed]

28.

Mahajan A, Goh V, Basu S, Vaish R, Weeks AJ, Thakur MH, et al. Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine? Clin Radiol. 2015;70:1060–82. [DOI] [PubMed]

29.

30.

Guha A, Goda JS, Dasgupta A, Mahajan A, Halder S, Gawde J, et al. Classifying primary central nervous system lymphoma from glioblastoma using deep learning and radiomics based machine learning approach-a systematic review and meta-analysis. Front Oncol. 2022;12:884173. [DOI] [PubMed] [PMC]

31.

Kandalgaonkar P, Sahu A, Saju AC, Joshi A, Mahajan A, Thakur M, et al. Predicting IDH subtype of grade 4 astrocytoma and glioblastoma from tumor radiomic patterns extracted from multiparametric magnetic resonance images using a machine learning approach. Front Oncol. 2022;12:879376. [DOI] [PubMed] [PMC]

32.

Baid U, Ghodasara S, Mohan S, Bilello M, Calabrese E, Colak E, et al. The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on brain tumor segmentation and radiogenomic classification. arXiv [Preprint]. 2021 [cited 2021 Sep 12]. Available from: https://arxiv.org/abs/2107.02314 [DOI]

33.

Chakrabarty N, Mahajan A, Patil V, Noronha V, Prabhash K. Imaging of brain metastasis in non-small-cell lung cancer: indications, protocols, diagnosis, post-therapy imaging, and implications regarding management. Clin Radiol. 2023;78:175–86. [DOI] [PubMed]

34.

Gao Q, Ma H, Wang B, Yao Y, Zhou J, Zhou J. Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients. Oncotarget. 2017;8:108840–7. [DOI] [PubMed] [PMC]

35.

Bhatt VR, D’Souza SP, Smith LM, Cushman-Vokoun AM, Noronha V, Verma V, et al. Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer. J Glob Oncol. 2016;3:208–17. [DOI] [PubMed] [PMC]

36.

Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108–11. [DOI] [PubMed] [PMC]

37.

Wadhwa S, Krishnab G, Malhotra M, Prabhash K, Noronha V, Joshi A, et al. Radiogenomic signatures of NSCLC brain metastases: a potential non-invasive imaging marker for ALK mutation. Ann Oncol. 2019;30:ii20. [DOI]

38.

Mahajan A, Prabhash K, Ghaytidak A, Noronah V, Joshi A, Patil V. 72PD MR imaging radiomics of NSCLC brain metastases: a potential targetable imaging biomarker for EGFR status. J Thorac Oncol. 2018;13:S39–40. [DOI]